Company · CIK 0001253689 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
CRESCENT BIOPHARMA, INC. · CBIO
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 16, 2026 SForm 4 → | Sep 18, 4:03 pm EDT | Ryan LynchSee Remarks | 240 | $17.90 | $4,296 | 13,631 | −1.73% | 10b5-1 |
| Sep 16, 2026 SForm 4 → | Sep 18, 4:03 pm EDT | Jan PinkasChief Scientific Officer | 658 | $17.90 | $11,778 | 21,581 | −2.96% | 10b5-1 |
| Sep 16, 2026 SForm 4 → | Sep 18, 4:02 pm EDT | Ellie Eunkyung ImChief Medical Officer | 623 | $17.90 | $11,152 | 21,446 | −2.82% | 10b5-1 |
| Sep 16, 2026 SForm 4 → | Sep 18, 4:02 pm EDT | Richard William ScalzoChief Financial Officer | 568 | $17.90 | $10,167 | 19,730 | −2.80% | 10b5-1 |
| Sep 16, 2026 SForm 4 → | Sep 18, 4:02 pm EDT | Barbara Harlin BisphamSee Remarks | 620 | $17.90 | $11,098 | 18,710 | −3.21% | 10b5-1 |
| Sep 16, 2026 SForm 4 → | Sep 18, 4:02 pm EDT | Joshua T BrummChief Executive Officer, Director | 9,447 | $16.91 | $159,775 | 271,765 | −3.36% | 10b5-1 |
| Sep 16, 2026 SForm 4 → | Sep 18, 4:01 pm EDT | Jonathan McNeillPresident and COO | 4,570 | $16.90 | $77,235 | 134,588 | −3.28% | 10b5-1 |
| Jul 16, 2026 PForm 4 → | Jul 20, 5:30 pm EDT | Fairmount Funds Management LLC +3Director, 10% Owner | 853,450 | $14.50 | $12,375,025 | 3,601,316 | +31.1% |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 16, 2026 PForm 4 → | Jul 20, 5:30 pm EDT | Fairmount Funds Management LLC +3Director, 10% Owner | 525,897 | $14.50 | $7,624,981 | 2,294,037 | — |